BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Summary by AI BETAClose X

BioNTech reported full-year 2025 revenues of €2.9 billion with a net loss of €1.1 billion, or an adjusted net loss of €0.1 billion, and a strong financial position with €17.2 billion in cash, cash equivalents, and security investments. The company anticipates 2026 total revenues between €2.0 billion and €2.3 billion, with adjusted R&D expenses projected at €2.2-2.5 billion and adjusted SG&A expenses between €700-800 million. A significant corporate development includes the planned establishment of an independent company by BioNTech's co-founders to focus on next-generation mRNA innovations, with a management transition expected by the end of 2026. The company also highlighted progress in its oncology pipeline, with six late-stage data readouts anticipated across various therapeutic modalities.

Disclaimer*

UK 100

Latest directors dealings